Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
Top Page
Galectin Therapeutics
(NASDAQ:GALT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.00
▼(-47.46% Downside)
Action:ReiteratedDate:01/31/26
The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, negative equity, and ongoing cash burn with rising debt). Technicals also remain bearish with the stock below major moving averages and negative MACD, despite near-oversold readings. Offsetting these risks, corporate updates around NAVIGATE results, FDA interactions, and insider funding are constructive but not enough to outweigh the current financial and technical headwinds.
Positive Factors
Promising NAVIGATE trial results
Phase 2b NAVIGATE results demonstrating antifibrotic benefit and a favorable safety profile materially strengthen belapectin's clinical proposition. Durable efficacy and tolerability raise the probability of a viable registration pathway and long-term commercial opportunity if pivotal trials confirm these signals.
Negative Factors
Weak balance sheet; negative equity
Severely negative equity and materially rising debt versus minimal assets signal accumulated losses and constrained financial flexibility. Over months this elevates refinancing and creditor risk, limits strategic options, and increases the probability of dilutive financings or restructuring if clinical progress stalls.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising NAVIGATE trial results
Phase 2b NAVIGATE results demonstrating antifibrotic benefit and a favorable safety profile materially strengthen belapectin's clinical proposition. Durable efficacy and tolerability raise the probability of a viable registration pathway and long-term commercial opportunity if pivotal trials confirm these signals.
Read all positive factors
Galectin Therapeutics (GALT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$188.92M
Dividend YieldN/A
Average Volume (3M)341.94K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue GrowthN/A
EPS Growth18.82%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,479,210
10 Day Avg. Volume287,288
30 Day Avg. Volume341,945
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)-0.78
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market Cap1.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.62K
Enterprise Value/Ebitda-9.93
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$179.69M
Galectin Therapeutics Business Overview & Revenue Model
Company Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibit...
How the Company Makes Money
Galectin Therapeutics primarily makes money through research and development collaborations, licensing agreements, and milestone payments related to its drug candidates. The company partners with larger pharmaceutical firms to advance the developm...
Galectin Therapeutics Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
4
Very Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.00K | -37.00K | -33.00K | -32.00K | -41.00K | -36.00K |
| EBITDA | -30.17M | -41.47M | -38.24M | -37.71M | -30.00M | -23.34M |
| Net Income | -37.30M | -47.05M | -41.07M | -38.78M | -30.53M | -23.46M |
Balance Sheet | ||||||
| Total Assets | 12.87M | 17.50M | 28.20M | 21.29M | 41.83M | 29.60M |
| Cash, Cash Equivalents and Short-Term Investments | 11.53M | 15.12M | 25.66M | 18.59M | 39.65M | 27.14M |
| Total Debt | 122.31M | 106.25M | 71.81M | 39.87M | 29.06M | 44.00K |
| Total Liabilities | 138.17M | 120.56M | 88.44M | 53.48M | 39.21M | 5.41M |
| Stockholders Equity | -125.30M | -103.07M | -60.24M | -32.19M | 2.62M | 24.19M |
Cash Flow | ||||||
| Free Cash Flow | -30.62M | -41.77M | -32.97M | -31.06M | -24.31M | -20.60M |
| Operating Cash Flow | -30.62M | -41.77M | -32.97M | -31.06M | -24.31M | -20.60M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 15.09M | 31.23M | 40.03M | 10.00M | 36.81M | 263.00K |
Galectin Therapeutics Technical Analysis
Negative
5.71
Price Trends
3.01
Negative
4.09
Negative
3.91
Negative
Market Momentum
-0.07
Positive
46.96
Neutral
34.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 3.02, above the 50-day MA of 3.01, and above the 200-day MA of 3.91, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 46.96 is Neutral, neither overbought nor oversold. The STOCH value of 34.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GALT.
Galectin Therapeutics Risk Analysis
Galectin Therapeutics disclosed 38 risk factors in its most recent earnings report. Galectin Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galectin Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $583.20M | -5.15 | -26.87% | ― | ― | 60.40% | |
52 Neutral | $687.96M | -3.80 | -50.23% | 14.68% | ― | 89.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $740.20M | -2.20 | 57.33% | ― | ― | 12.32% | |
50 Neutral | $156.76M | -1.20 | -85.20% | ― | ― | 46.68% | |
47 Neutral | $240.19M | -1.93 | -48.94% | ― | -80.88% | -388.61% | |
46 Neutral | $188.92M | -8.32 | 32.59% | ― | ― | 18.82% |
* Healthcare Sector Average
GALT
Galectin Therapeutics
2.93
1.29
78.66%
OMER
Omeros
10.44
1.92
22.54%
VYGR
Voyager Therapeutics
4.03
0.39
10.71%
TECX
Tectonic Therapeutic
31.06
12.05
63.39%
JBIO
Jade Biosciences
13.95
4.77
51.96%
TNYA
Tenaya Therapeutics
0.72
0.08
12.64%
Galectin Therapeutics Corporate Events
Executive/Board Changes
Galectin Therapeutics Approves Retention Bonuses for Key Executives
Neutral
Jan 21, 2026
On January 16, 2026, Galectin Therapeutics’ board of directors, acting on the recommendation of its compensation committee, approved cash retention bonuses for two key executives: a $300,000 bonus for Chief Medical Officer Dr. Khurram Jamil ...
Executive/Board Changes
Galectin Therapeutics announces board resignation of Marc Rubin
Neutral
Jan 12, 2026
On January 10, 2026, Galectin Therapeutics, Inc. announced that Marc Rubin resigned from its Board of Directors. The company specified that Rubin’s departure did not stem from any disagreement regarding its operations, policies or practices,...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Galectin Advances Belapectin Program, Secures New Insider Financing
Positive
Dec 19, 2025
On December 19, 2025, Galectin Therapeutics reported that the U.S. Food and Drug Administration provided a written response to the company’s Type C meeting request on the development program for belapectin, leading the company to believe the...
Shareholder Meetings
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
Neutral
Dec 8, 2025
At the 2025 Annual Meeting of Stockholders on December 3, 2025, Galectin Therapeutics‘ stockholders elected the nominated directors and approved a non-binding advisory resolution on executive compensation. They also ratified Cherry Bekaert L...
Business Operations and StrategyShareholder Meetings
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
Positive
Dec 3, 2025
On December 3, 2025, Galectin Therapeutics presented compelling results from its NAVIGATE trial at its Annual Meeting of Stockholders. The trial focused on belapectin’s efficacy in treating MASH cirrhosis and portal hypertension, showing sig...
Business Operations and StrategyProduct-Related Announcements
Galectin Therapeutics Presents Promising NAVIGATE Trial Results
Positive
Nov 10, 2025
On November 10, 2025, Galectin Therapeutics announced the presentation of its NAVIGATE trial results at the AASLD 2025 Annual Meeting. The Phase 2b trial evaluated belapectin, a galectin-3 inhibitor, in patients with compensated MASH cirrhosis and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.